2026 Q2 Portfolio Activity
In 2026 Q2, NEA Management Company, LLC maintained a portfolio of 27 distinct positions. The most significant new addition was Karyopharm Therapeutics Inc., now representing 0.35% of the total fund value. They heavily accumulated shares in Spyglass Pharma, Inc., increasing the position by 128.6%. Conversely, NEA Management Company, LLC completely exited their position in Arcellx, Inc..
Position History
hover any row below to update
Loading…
Total Positions
27
Quarter
2026 Q2
Top Holding
TRVI (15.5%)
Top 10 Concentration
89.8%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-27 of 27
NEA Management Company, LLC Full Holdings List — 2026 Q2
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
TRVI
Trevi Therapeut...
|
Healthcare | 15.53% | 8.97% |
#1
3
Prev: #4
|
7.0 |
—
|
no change | no change |
P
S
|
13,222,228 | $246,594,552 | 2019 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MBX
MBX Biosciences...
|
Healthcare | 12.56% | 6.13% |
#2
5
Prev: #7
|
6.5 |
—
|
no change | no change |
P
S
|
3,614,486 | $199,519,627 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GLUE
Monte Rosa Ther...
|
Healthcare | 11.72% | 7.19% |
#3
3
Prev: #6
|
6.0 |
—
|
no change | no change |
P
S
|
7,692,298 | $186,153,612 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CELC
Celcuity Inc.
|
Healthcare | 11.27% | 14.83% |
#4
2
Prev: #2
|
4.5 |
—
|
-575,000 | -25.2% |
P
S
|
1,710,561 | $178,958,892 | 2022 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
Spyglass Pharma...
|
|
Unknown | 10.36% | 10.89% |
#5
2
Prev: #3
|
5.5 |
—
|
no change | no change |
P
S
|
7,392,301 | $164,552,620 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
SVRA
Savara, Inc.
|
Healthcare | 9.49% | 7.60% |
#6
1
Prev: #5
|
4.8 |
—
|
no change | no change |
P
S
|
24,471,264 | $150,742,986 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ZBIO
Zenas BioPharma...
|
Healthcare | 6.43% | 4.47% |
#7
1
Prev: #8
|
3.6 |
—
|
no change | no change |
P
S
|
4,023,219 | $102,109,298 | 2024 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
COUR
Coursera, Inc.
|
Consumer Defensive | 4.57% | 4.26% |
#8
1
Prev: #9
|
2.8 |
—
|
no change | no change |
P
S
|
12,867,769 | $72,574,217 | 2021 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
AUPH
Aurinia Pharmac...
|
Healthcare | 4.24% | 3.34% |
#9
1
Prev: #10
|
2.7 |
—
|
no change | no change |
P
S
|
3,969,834 | $67,368,083 | 2014 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CRSP
CRISPR Therapeu...
|
Healthcare | 3.64% | 2.86% |
#10
2
Prev: #12
|
2.5 |
—
|
no change | no change |
P
S
|
1,058,570 | $57,734,408 | 2016 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ORIC
ORIC Pharmaceut...
|
Healthcare | 2.81% | 2.97% |
#11
Prev: #11
|
2.1 |
—
|
no change | no change |
P
S
|
4,118,621 | $44,604,665 | 2024 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
PHAT
Phathom Pharmac...
|
Healthcare | 1.34% | 1.24% |
#12
1
Prev: #13
|
1.5 |
—
|
no change | no change |
P
S
|
1,960,169 | $21,267,834 | 2023 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KRRO
Korro Bio, Inc.
|
Healthcare | 1.08% | 0.84% |
#13
2
Prev: #15
|
1.4 |
—
|
no change | no change |
P
S
|
1,297,893 | $17,106,230 | 2023 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
N/A
X4 Pharmaceutic...
|
|
Unknown | 0.95% | 0.76% |
#14
2
Prev: #16
|
1.4 |
—
|
no change | no change |
P
S
|
3,233,743 | $15,101,580 | — | 13F Filing | 2026-06-30 | 2026-08-14 | ||
|
CSBR
Champions Oncol...
|
Healthcare | 0.66% | 0.56% |
#15
2
Prev: #17
|
1.3 |
—
|
no change | no change |
P
S
|
1,713,720 | $10,556,515 | 2015 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
NKTX
Nkarta, Inc.
|
Healthcare | 0.64% | 0.43% |
#16
4
Prev: #20
|
1.3 |
—
|
no change | no change |
P
S
|
3,568,781 | $10,099,650 | 2020 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
CVRX
CVRx, Inc.
|
Healthcare | 0.63% | 1.09% |
#17
3
Prev: #14
|
0.8 |
—
|
-71,643 | -3.5% |
P
S
|
1,954,440 | $10,045,822 | 2021 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
BDTX
Black Diamond T...
|
Healthcare | 0.52% | 0.54% |
#18
Prev: #18
|
1.2 |
—
|
no change | no change |
P
S
|
4,448,757 | $8,230,200 | 2020 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
KPTI
Karyopharm Ther...
|
Healthcare | 0.35% | — |
#19
Prev: #—
|
3.6 |
—
|
576,780 | — |
NEW
|
576,780 | $5,635,141 | 2026 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IVA
Inventiva SA
|
Healthcare | 0.35% | 0.46% |
#20
1
Prev: #19
|
1.1 |
—
|
no change | no change |
P
S
|
1,462,586 | $5,528,575 | 2020 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
LONA
LeonaBio, Inc.
|
Healthcare | 0.27% | 0.27% |
#21
Prev: #21
|
1.1 |
—
|
no change | no change |
P
S
|
464,398 | $4,267,818 | 2025 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
SNTI
Senti Bioscienc...
|
Healthcare | 0.26% | 0.17% |
#22
Prev: #22
|
1.1 |
—
|
no change | no change |
P
S
|
3,775,615 | $4,153,177 | 2022 Q2 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
MRKR
Marker Therapeu...
|
Healthcare | 0.15% | 0.12% |
#23
Prev: #23
|
1.1 |
—
|
no change | no change |
P
S
|
1,625,678 | $2,389,747 | 2023 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
OKUR
OnKure Therapeu...
|
Healthcare | 0.14% | 0.11% |
#24
Prev: #24
|
1.1 |
—
|
no change | no change |
P
S
|
478,548 | $2,182,179 | 2024 Q4 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
IMA
ImageneBio, Inc...
|
Healthcare | 0.02% | 0.01% |
#25
1
Prev: #26
|
1.0 |
—
|
no change | no change |
P
S
|
50,005 | $295,030 | 2025 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
GOSS
Gossamer Bio, I...
|
Healthcare | 0.01% | 0.02% |
#26
1
Prev: #25
|
1.0 |
—
|
no change | no change |
P
S
|
1,000,000 | $164,600 | 2022 Q3 | 13F Filing | 2026-06-30 | 2026-08-14 | |||
|
ACLX
Arcellx, Inc.
|
Healthcare | 0.00% | 19.88% |
Sold All 😨
(Was: #1) |
0.0 |
—
|
-3,045,262 | -100.0% |
CLOSED
|
— | $— | 2022 Q1 | 13F Filing | 2026-06-30 | 2026-08-14 |
Showing 1-27 of 27 holdings